Celularity (CELU) Operating Income (2019 - 2025)
Celularity (CELU) posted quarterly Operating Income of -$22.1 million for Q4 2025, down 137.69% year-over-year from $58.5 million in Q4 2024, and down 70.99% quarter-over-quarter from -$12.9 million in Q3 2025.
Celularity (CELU) Operating Income (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Operating Income for 7 consecutive years, with -$22.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Income fell 137.69% year-over-year to -$22.1 million; the TTM figure through Dec 2025 stood at -$61.3 million (down 59.83% YoY), while the FY2025 annual figure was -$61.3 million, down 59.83% from the prior year.
- Operating Income eased to -$22.1 million in Q4 2025 per CELU's latest filing, from -$12.9 million in the prior quarter.
- Across five years, Operating Income topped out at $17.5 million in Q4 2022 and bottomed at -$99.3 million in Q3 2023.
- Historically, Operating Income has averaged -$21.3 million across 5 years, with a median of -$12.2 million in 2024.
- On a YoY basis, Operating Income climbed as much as 326.76% in 2021 and fell as far as 29007.3% in 2021.
- Celularity's Operating Income stood at -$15.0 million in 2021, then jumped by 216.95% to $17.5 million in 2022, then fell by 23.85% to $13.3 million in 2023, then plunged by 169.7% to -$9.3 million in 2024, then tumbled by 137.69% to -$22.1 million in 2025.
- Business Quant data shows CELU's Operating Income at -$22.1 million in Q4 2025, -$12.9 million in Q3 2025, and -$15.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | -22.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -22.06 Mn |
| Sep 30, 2025 | -12.90 Mn |
| Jun 30, 2025 | -15.86 Mn |
| Mar 31, 2025 | -10.49 Mn |
| Dec 31, 2024 | -9.28 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -10.18 Mn |
| Mar 31, 2024 | -7.38 Mn |
| Dec 31, 2023 | 13.32 Mn |
| Sep 30, 2023 | -99.26 Mn |
| Jun 30, 2023 | -42.48 Mn |
| Mar 31, 2023 | -63.87 Mn |
| Dec 31, 2022 | 17.49 Mn |
| Sep 30, 2022 | -5.65 Mn |
| Jun 30, 2022 | 4.18 Mn |
| Mar 31, 2022 | -41.61 Mn |
| Dec 31, 2021 | -14.95 Mn |
| Sep 30, 2021 | 10.90 Mn |
| Jun 30, 2021 | -60.61 Mn |
| Mar 31, 2021 | -44.40 Mn |